Adil Doganay Duru

Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D

Ece Canan Sayitoğlu, Anna‐Maria Georgoudaki, Michael Chrobok et al. · Frontiers in Immunology · 2020 · 57 citations · Full text

Life Sciences, Immunology, Oncology +17

The Use of Novel Drugs Can Effectively Improve Response, Delay Relapse and Enhance Overall Survival in Multiple Myeloma Patients with Renal Impairment

Katarina Uttervall, Adil Doganay Duru, Johan Lund et al. · PLoS ONE · 2014 · 54 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Successive crystal structure snapshots suggest the basis for MHC class I peptide loading and editing by tapasin

Ida Hafstrand, Ece Canan Sayitoğlu, Anca Apavaloaei et al. · Proceedings of the National Academy of Sciences · 2019 · 46 citations · Full text

Life Sciences, Immunology, Molecular Biology +17

Engineering antigen‐specific NK cell lines against the melanoma‐associated antigen tyrosinase via TCR gene transfer

Ayhan Parlar, Ece Canan Sayitoğlu, Didem Özkazanç et al. · European Journal of Immunology · 2019 · 42 citations · Full text

Life Sciences, Immunology, Oncology +17

ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma

Nadia Mensali, Hakan Köksal, Sandy Joaquina et al. · Nature Communications · 2023 · 42 citations · Full text

Medicine, Cancer Biology, Oncology +17